SGLT2 inhibitors in type 2 diabetes: time to flozinate?
Sodium-glucose cotransporter-2 (SGLT2) inhibitors have a wide range of benefits in people with insufficiently controlled type 2 diabetes. Claire Davies provides an overview of these drugs to support safe use in primary care
Sodium-glucose cotransporter-2 (SGLT2) inhibitors, sometimes also referred to as ‘gliflozins’ or ‘flozins’, are an established class of medications used for the treatment of insufficiently controlled type 2 diabetes. This article provides a summary of everything nursing staff in primary care need to know about the use of SGLT2 inhibitors for type 2 diabetes to support safe prescribing, monitoring and use.
This article outlines the place of sodium-glucose cotransporter-2 (SGLT2) inhibitor therapy in type 2 diabetes, while highlighting relevant cautions, contraindications and side-effects, with the aim of supporting safe prescribing and use of SGLT2 inhibitors for glycaemic control in adults with type 2 diabetes. After reading this article, the reader should:
SGLT2 inhibitors, sometimes also referred to as ‘gliflozins’ or ‘flozins’ are an established class of medications, which are licensed for the treatment of (Table 1):
The class of SGLT2 inhibitors includes: canagliflozin, dapagliflozin, empagliflozin and ertugliflozin (Joint Formulary Committee, 2022). It is important to note not every drug in the class is licensed for all of the indications listed above. A summary of current UK licenses for these drugs is shown in Table 1. Please note this is current at the time of print and likely to change as trial data is being released rapidly. It is also important to note while drugs may be licensed, they may not have NICE approval for all indications). Please consult the individual summary of product characteristics (SmPC) or local prescribing information for dosing recommendations and specific indications before prescribing SGLT2 inhibitor therapies.
Register now to continue reading
Thank you for visiting Practice Nursing and reading some of our peer-reviewed resources for general practice nurses. To read more, please register today. You’ll enjoy the following great benefits:
Limited access to clinical or professional articles
New content and clinical newsletter updates each month